BR0214832A - Inibição de tristetraprolina para proteção do coração contra danos cardìacos - Google Patents

Inibição de tristetraprolina para proteção do coração contra danos cardìacos

Info

Publication number
BR0214832A
BR0214832A BR0214832-3A BR0214832A BR0214832A BR 0214832 A BR0214832 A BR 0214832A BR 0214832 A BR0214832 A BR 0214832A BR 0214832 A BR0214832 A BR 0214832A
Authority
BR
Brazil
Prior art keywords
heart
inhibition
tristetraproline
protect
damage
Prior art date
Application number
BR0214832-3A
Other languages
English (en)
Inventor
Franz-Werner Kluxen
Bernd Hentsch
Thomas Ehring
Marian Braendle
Joerg Dietrich Hoheisel
Marcus Frohme
Dimitri Zubakov
Original Assignee
Merck Patent Ges Mit Beschaenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschaenk filed Critical Merck Patent Ges Mit Beschaenk
Publication of BR0214832A publication Critical patent/BR0214832A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"INIBIçãO DE TRISTETRAPROLINA PARA PROTEçãO DO CORAçãO CONTRA DANOS CARDìACOS". A presente invenção refere-se a compostos adequados para o tratamento de condições que podem ser melhoradas, pelo menos em parte, através do aumento da produção de TNF<244>. A invenção refere-se ainda a ensaios para a identificação de um indivíduo sob alto risco de ou sofrendo de tais condições e a métodos de avaliação de compostos quanto à sua habilidade em aumentar a biossíntese de TNF<244>.
BR0214832-3A 2001-12-12 2002-11-30 Inibição de tristetraprolina para proteção do coração contra danos cardìacos BR0214832A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01129564 2001-12-12
PCT/EP2002/013545 WO2003054541A2 (en) 2001-12-12 2002-11-30 Inhibition of tristetraproline for protection of the heart from cardiac injuries

Publications (1)

Publication Number Publication Date
BR0214832A true BR0214832A (pt) 2004-08-31

Family

ID=8179511

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214832-3A BR0214832A (pt) 2001-12-12 2002-11-30 Inibição de tristetraprolina para proteção do coração contra danos cardìacos

Country Status (17)

Country Link
US (2) US20050084860A1 (pt)
EP (1) EP1454142B1 (pt)
JP (1) JP2005512579A (pt)
KR (1) KR20040068559A (pt)
CN (1) CN1602427A (pt)
AR (1) AR037788A1 (pt)
AT (1) ATE538388T1 (pt)
AU (2) AU2002352201B2 (pt)
BR (1) BR0214832A (pt)
CA (1) CA2470148C (pt)
ES (1) ES2378228T3 (pt)
HU (1) HUP0402153A2 (pt)
MX (1) MXPA04005628A (pt)
PL (1) PL369849A1 (pt)
RU (1) RU2004121681A (pt)
WO (1) WO2003054541A2 (pt)
ZA (1) ZA200405449B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100012714A (ko) * 2008-07-29 2010-02-08 재단법인서울대학교산학협력재단 Ｒｎａ 분자와 단백질 사이의 상호작용을 조절하는 물질을동정하기 위한 분석 방법
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
AU3130597A (en) * 1996-05-16 1997-12-05 Duke University Tristetraprolin
AU6638800A (en) * 1999-08-13 2001-03-13 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Ttp-related zinc finger domains and methods of use

Also Published As

Publication number Publication date
AU2002352201A1 (en) 2003-07-09
AU2009201627B2 (en) 2012-09-06
JP2005512579A (ja) 2005-05-12
ES2378228T3 (es) 2012-04-10
RU2004121681A (ru) 2005-04-20
PL369849A1 (en) 2005-05-02
CN1602427A (zh) 2005-03-30
ATE538388T1 (de) 2012-01-15
AU2009201627A1 (en) 2009-05-21
WO2003054541A3 (en) 2003-11-06
WO2003054541A2 (en) 2003-07-03
CA2470148C (en) 2015-03-17
AR037788A1 (es) 2004-12-01
MXPA04005628A (es) 2004-12-06
AU2002352201B2 (en) 2009-01-29
EP1454142A2 (en) 2004-09-08
KR20040068559A (ko) 2004-07-31
HUP0402153A2 (hu) 2005-01-28
US20050084860A1 (en) 2005-04-21
ZA200405449B (en) 2005-06-20
EP1454142B1 (en) 2011-12-21
CA2470148A1 (en) 2003-07-03
US20090104182A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
GEP20032920B (en) Inhibitors of Phospholipase Enzymes
WO2005104416A3 (en) Rights management inter-entity message policies and enforcement
WO2001083547A3 (en) Anti-inflammatory compounds and uses thereof
BR9911666A (pt) Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica
TR199903287T2 (xx) Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
EP2298299A3 (en) O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
BR9909819A (pt) Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
MY121808A (en) Module for interconnecting two monopair lines
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
BR9802494A (pt) Método para determinar a espessura de uma amostra ótica.
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
BR0214832A (pt) Inibição de tristetraprolina para proteção do coração contra danos cardìacos
BR9915031A (pt) Processos e composições para a inibição de polimerização de hidrocarbonetos etilenicamente insaturados
Nakagawa et al. Propyl gallate-induced DNA fragmentation in isolated rat hepatocytes
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
IT1283110B1 (it) Composti a scheletro colchicinico,loro uso come farmaci e composizioni che li contengono
WO2000057871A3 (en) Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
FR2833325B1 (fr) Dispositif de freinage d&#39;un vehicule
BR0212583A (pt) Agonistas i para retinóides de alquil uréia
Rishi et al. Nitric oxide induces apoptosis in cutaneous T cell lymphoma (HuT-78) by downregulating constitutive NF-κB
BR0207716A (pt) Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos
WO2002069890A3 (en) Methods of identifying agents affecting atrophy and hypertrophy

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]